112 Results
Sort By:
Published on January 16, 2024
Overexpression of PIEZO2 stood out as an independent risk factor for men with gastric cancer (GC) who had poor overall survival in a study led by researchers from Tongji University School of Medicine and Shanghai University of Traditional Chinese Medicine. Interestingly, the biomarker did not have the same impact in…
Published on July 19, 2023
A new multicenter research effort in Japan, published in the journal Science Signaling, suggests that infection with Helicobacter pylori cagA+ strains significantly increases the risk of developing gastric cancer. The preclinical in vitro and vivo study, in multiple models, offers up a potential target for preventing gastric cancer development by H.…
Published on July 12, 2023
A new study in Cancer Cell reveals evolutionary clues in the tumor microenvironment during gastric cancer progression. Researchers from the University of Texas MD Anderson Cancer Center learned that the presence of certain types of cell groupings were linked with clinical outcomes. The study provides a high-resolution gastric cancer tumor…
Published on April 5, 2023
New evidence finds nine germline pathogenic variants, combined with H. pylori infection, raise gastric cancer risk considerably. Several of these variants are involved in homologous-recombination. It has been estimated that germline mutations cause only one to three percent of gastric cancers. These new findings suggest hereditary risk is more important…
Published on November 23, 2022
One of the top selling drugs in the world, Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumal), is moving into new territory. The company just reported positive topline results from a phase III trial of KEYTRUDA in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal…
Published on February 16, 2022
Scientists at the Mayo Clinic Cancer Center in Florida say a recent study is validating the use of genomic sequencing to predict the likelihood that patients with gastric cancer will derive benefit from chemotherapy or from immunotherapy. Their paper (“Development and validation of a prognostic and predictive 32-gene signature for…
Published on February 15, 2022
A gene signature generated from a machine learning algorithm appears to predict the likelihood of which patients with gastric cancer will benefit from chemotherapy or immunotherapy, according to a new study. “We were pleased that our 32-gene signature provided not only prognostic information, but also predicted patient benefit from chemotherapy…
Published on May 12, 2021
Leap Therapeutics and Flagship Bioscience have developed an image analysis RNAscope assay that is being used for prospective patient enrollment in a clinical trial. The companies believe this is the first example of an RNAscope assay using a digital image analysis solution for patient enrollment. They describe how to the…
Published on April 19, 2021
The FDA has approved Bristol-Myers Squibb’s monoclonal antibody Opdivo (nivolumab) for first-line treatment of gastric cancer in combination with fluoropyrimidine- and platinum-containing chemotherapy. Cancer cells release proteins that can protect themselves from immune T cells that are seeking to destroy them. Nivolumab is a checkpoint inhibitor drug and acts by…
Published on January 22, 2021
Use of a highly personalized approach to treatment including specific monoclonal antibodies tailored to a patient’s biomarker profile improves outcomes for patients with metastatic gastroesophageal cancers, shows research from the University of Chicago. The phase II trial split patients into eight groups depending on the biomarker profile of their individual…
Published on January 29, 2020
A blood test to predict recurrence of gastric cancer post-surgery has been developed by researchers at the Johns Hopkins Kimmel Cancer Center in Baltimore and colleagues in the Netherlands. A description of their test, which is still experimental, was published online Jan. 27 in the journal Nature Communications. Alessandro Leal,…
Published on November 18, 2022
One of the hottest biomarkers in cancer research, CLDN18.2, just got another major nod. Astellas Pharma has announced positive results from a large Phase III trial (SPOTLIGHT) of zolbetuximab in CLDN18.2-positive and HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Full data from the trial was not released. Astellas bought…
Published on November 12, 2024
To help cancer care providers and others stay current on the impact of genetic discoveries on cancer care, the National Comprehensive Cancer Network (NCCN) has published an expanded Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. The NCCN is an alliance of leading cancer…
Published on November 6, 2024
Men with treatment-emergent neuroendocrine prostate cancer (t-NEPC) could benefit from human epidermal growth factor receptor (HER)2 testing and treatment with trastuzumab deruxtecan (T-DXd), suggest researchers from the Washington DC Veterans Affairs Medical Center and The George Washington University School of Medicine. They report in the Annals of Internal Medicine, the…
Published on October 2, 2024
A study led by researchers at the Duke Cancer Institute has uncovered new insights into the role of estrogens in cancer growth, particularly in breast cancers that lack estrogen receptors. The research, published in Science Advances, describes how estrogens not only decrease the ability of the immune system to attack…